|
|||||
|
|
Randomized trial of asunaprevir plus peginterferon alfa and ribavirin for previously untreated genotype 1 or 4 chronic hepatitis C |
|
| Authors: | Jean-Pierre Bronowicki Vlad Ratziu Adrian Gadano Paul J. Thuluvath Fernando Bessone Claudia T. Martorell Stanislas Pol Ruben Terg Ziad Younes Bing He Timothy Eley David Cohen Fei Yu Dennis Hernandez Fiona McPhee Patricia Mendez Eric Hughes |
| Affiliation: | 1 INSERM U954, Centre Hospitalier Universitaire de Nancy, Université de Lorraine, Vandoeuvre les Nancy, France;2 Groupe Hospitalier Pitié Salpêtrière, Université Pierre et Marie Curie, Paris, France;3 Hospital Italiano de Buenos Aires, Buenos Aires, Argentina;4 Mercy Medical Center, Baltimore, MD, USA;5 Hospital Provincial del Centenario, University of Rosario School of Medicine, Rosario, Argentina;6 The Research Institute, Springfield, MA, USA;7 Université Paris Descartes, INSERM U-1016, APHP, Hôpital Cochin, Paris, France;8 Universidad del Salvador Hospital de Gastroenterología Bonorino Udaondo, Buenos Aires, Argentina;9 Gastro One, Germantown, TN, USA;10 Bristol-Myers Squibb, Princeton, NJ, USA;11 Bristol-Myers Squibb, Wallingford, CT, USA |
| Abstract: | |
| Keywords: | HCV, hepatitis C virus PegIFNα, peginterferon alfa RBV, ribavirin DAA, direct-acting antiviral BID, twice daily SVR24, sustained virologic response 24 weeks posttreatment PDR, protocol-defined response LLOQ, lower limit of quantification EVR, early virologic response ALT, alanine aminotransferase ULN, upper limit of normal HBV, hepatitis B virus HIV, human immunodeficiency virus LOD, limit of detection EOT, End-of-treatment eRVR, extended rapid virologic response RVR, rapid virologic response cEVR, complete early virologic response SVR12, sustained virologic response at 12 weeks posttreatment AE, adverse event mITT, modified intent-to-treat CI, confidence interval AST, aspartate aminotransferase |
| 本文献已被 ScienceDirect 等数据库收录！ | |